Biodesix, Inc. Common Stock

Day range

$21.11 – $23.70

Open

$23.66

Prev close

$23.94

Volume

139.52K

Market cap

$252.59M

Shares out

10.55M

P/E

—

P/S

2.45

P/B

27.62

P/FCF

—

ROE

-303.6%

ROA

-29.1%

Debt/Equity

5.12

Div yield

0.00%

As of Oct 22, 2026

• Shareholder meetingsMay 20, 2026

  At the Annual Meeting, both director nominees were elected, the compensation of the Company's named executive officers was approved on a non-binding advisory basis, the frequency of solicitation of advisory votes to approve named executive officer compensation was approved on a non-binding advisory basis and the appointment of KPMG LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026 was ratified.

• Exchange listingOct 1, 2025

  On September 26, 2025, Biodesix, Inc., a Delaware corporation (the "Company") received a letter from the Nasdaq Listing Qualifications Department of the Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5450(a)(1) (the "Minimum Bid Price Requirement") for continued listing on The Nasdaq Global Market.

• Shareholder returnsSep 15, 2025

  On September 15, 2025, Biodesix, Inc., a Delaware corporation (the "Company"), effected a one-for-twenty reverse stock split ("Reverse Stock Split") of the Company's common stock, par value $0.001 (the "Common Stock"). On September 4, 2025, the Board approved the Reverse Stock Split at a ratio of one-for-twenty.

• Shareholder returnsSep 11, 2025

  The Reverse Stock Split is expected to become effective on September 15, 2025 as of 12:01 a.m. Eastern Time (the "Effective Time"), with shares to begin trading on a split-adjusted basis at market open on September 15, 2025. In connection with the Reverse Stock Split, every 20 shares of the Company's Common Stock issued and outstanding as of the Effective Time will be automatically converted into one share of the Company's Common Stock.

• Shareholder meetingsMay 21, 2025

  At the Annual Meeting, both director nominees were elected, the appointment of KPMG LLP as the Company's independent registered public accounting firm for the year ending December 31, 2025 was ratified, the amendment to the Company's amended and restated certificate of incorporation to effect a reverse stock split of the Company's Common Stock, at a ratio ranging from any whole number between 1-for-2 and 1-for-20 inclusive, as determined by our board of directors in its discretion, subject to our board of directors' authority to abandon such amendments was approved, and the Company's Amended and Restated Employee Stock Purchase Plan to increase the available shares of the Company's Common Stock under the plan by 1,451,500 and to increase the maximum number of shares of the Company's Common Stock that may be provided as the result of the plan's annual automatic increase to 3,000,000 shares of the Company's Common Stock was approved.

Days to cover

1.8

Short interest

201.85K

Avg volume

109.84K

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Biodesix Adds Digital Diagnostics to Lung Pipeline, Creating New Growth Platform Combining Blood and Imaging Biomarkers
  positiveGlobeNewswire Inc.· Oct 19, 2026
• Biodesix to Present New Real-World Evidence Supporting Integration of Nodify Lung® Testing into Routine Lung Nodule Care at CHEST 2026
  positiveGlobeNewswire Inc.· Oct 13, 2026
• Beat the Market Like Zacks: Thermo Fisher, Cricut, Shopify in Focus
  positiveZacks Investment Research· Oct 5, 2026
• Biodesix to Participate in Upcoming Investor Conferences
  positiveGlobeNewswire Inc.· Sep 3, 2026
• Biodesix to Report Second Quarter 2026 Financial Results on August 5, 2026
  neutralGlobeNewswire Inc.· Jul 22, 2026